The MMF/DZB Study

MMF/DZB ineffective in saving beta cells in newly diagnosed patients

A two-year TrialNet study in North America and Europe researched the effects of the drugs mycophenolate mofetil (MMF) and daclizumab (DZB) on 126 people newly diagnosed with type 1 diabetes.

The study ended in 2008 due to the failure of MMF, used alone and with DZB, to slow the destruction of the participants’ beta (insulin-producing) cells.

Type 1 diabetes is a chronic and progressive autoimmune disease where one’s own immune system attacks specific tissues in the body. The use of drugs to control the autoimmune response has been successful in the treatment of other autoimmune diseases. Also, other drugs have helped protect beta cell function in other type 1 diabetes studies. In this study with these two particular drugs, neither positive result occurred.

TrialNet is a network of 21 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes. Learn More >